Market Cap | 3.05M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.08M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -16.00% |
Sales | 4.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -60.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | - | Quick Ratio | 0.07 | Shares Outstanding | 104.48M | 52W Low Chg | 13.00% |
Insider Own | 37.46% | ROA | -47.50% | Shares Float | 60.23M | Beta | 1.86 |
Inst Own | 11.52% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.05 |
Gross Margin | 76.09% | Profit Margin | -88.04% | Avg. Volume | 223,441 | Target Price | - |
Oper. Margin | -44.60% | Earnings Date | - | Volume | 41,406 | Change | 4.67% |
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The company offers its dietary supplements products under the RCM System, stemrelease3, Stemflo MigraStem, OraStem, and D-Fuze brand names; and skincare products under the Cellect One brand name. It serves through independent distributors. Stemtech Corporation is headquartered in Naples, Florida.